|
Mar 4
|
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
|
|
Feb 4
|
Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.
|
|
Feb 2
|
CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know
|
|
Jan 30
|
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
|
|
Jan 30
|
Is CRISPR Therapeutics a Buy in the New Bull Market?
|
|
Jan 23
|
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
|
|
Jan 22
|
Cathie Wood’s Latest Stock Picks: 11 Biggest Positions
|
|
Jan 22
|
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
|
|
Jan 21
|
Could Editas Medicine Become the Next CRISPR Therapeutics?
|
|
Jan 21
|
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
|
|
Jan 20
|
3 High-Flying Stocks That Could Soar Even More in 2024
|
|
Jan 19
|
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
|
|
Jan 19
|
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
|
|
Jan 17
|
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
|
|
Jan 16
|
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
|
|
Jan 16
|
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
|
|
Jan 16
|
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
|
|
Jan 15
|
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
|
|
Jan 15
|
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
|
|
Jan 15
|
Down 88%, Could Editas Medicine Be a Good Investment Now?
|